Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies

Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies

Therapeutic monoclonal antibodies (mAbs) are often designed to not only bind targets via their antigen-binding domains (Fabs) but to also engage with cell surface receptors, FcγRs and FcRn, through their Fc regions, which may result in a variety of functional outcomes, including antibody- dependent...

Full description

Saved in:
Bibliographic Details
Main Authors: Frank R. Brennan, J. Ryan Polli, Jean Sathish, Melissa Ramones, Babette Wolf, Tilman Schlothauer, Shirley J. Peters, Curtis C. Maier, Changhua Ji, David L. Wensel, Derrick Witcher, Patricia C. Ryan, T. Scott Manetz, Adriano Flora, Brian Soper, Birgit Fogal, Lindsey Dzielak, Xiaoting Wang, Prathap Nagaraja Shastri, Karen Price, Michael Doyle, Nidhi Sharda, Mary Struthers, Maximilian Brinkhaus, Bianca Balbino, Eric Stefanich, Masaki Honda, Jan Terje Andersen, Shermaine Mitchell-Ryan, David P. Humphreys
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:mAbs
Subjects:
Effector function
Fc enhancement
Fc receptor blockade
Fc receptors
Fc silencing
monoclonal antibody
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2025.2505092
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2025.2505092

Similar Items